NASDAQ
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6 bil...
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B...
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNAÂ (talazoparib), an oral poly ADP-ri...
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Famil...
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall...
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.74 per share ...
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and i...
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs....
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
No price data available for this timeframe.